Susceptibility of 2,252 Pseudomonas aeruginosa Clinical Isolates Over 4 Years to 9 Antimicrobials in a Tertiary Greek Hospital.
Sofia Maraki, Elpis Mantadakis, Eleni Nioti...
https://pubmed.ncbi.nlm.nih.gov/26302835/Actively Recruiting
Led by Mansoura University · Updated on 2025-07-04
120
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research evaluates the effectiveness and safety of two dosing methods for colistin, an antibiotic used to treat infections caused by multi-drug-resistant and extensively drug-resistant Gram-negative bacteria in critically ill patients. These infections, especially common in intensive care units, pose a significant threat due to increasing antibiotic resistance, particularly in Saudi Arabia. The study focuses on comparing fixed dose and weight-based dose strategies in both obese and non-obese patients. Participants will be randomly assigned to one of two groups. One group receives intravenous colistin using a fixed dose strategy based on creatinine clearance, with a loading dose of 9 MIU equal to 300 mg of colistin base activity followed by maintenance doses every 12 hours. The other group receives colistin dosed based on body weight, with a loading dose calculated as four times the patients weight in kilograms, which may exceed 300 mg. Both dosing strategies will be administered intravenously in the intensive care unit setting. During the study, patients will be monitored for clinical and microbiological success in eliminating infections, assessed 14 days after starting colistin treatment. Safety will also be closely watched, particularly for kidney-related side effects. Researchers will collect data on how well the infection is cleared and observe any toxic effects from the treatment. The trial will last throughout the treatment period and follow-up to assess outcomes and safety in critically ill patients.
CONDITIONS
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
A
Abdulmajeed S Alharbi, Master
M
Mona M El-Tamalawy, Master
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mansoura University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 days post colistin initiation
Participants receive intravenous colistin using either the EMA fixed dose strategy or the US FDA weight-based dosing strategy to treat multidrug-resistant Gram-negative bacterial infections.
Daily dosing with clinical and safety assessments during treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sofia Maraki, Elpis Mantadakis, Eleni Nioti...
https://pubmed.ncbi.nlm.nih.gov/26302835/Jian Li, Roger L Nation, John D Turnidge...
https://pubmed.ncbi.nlm.nih.gov/16931410/Mansoura University
Lead Sponsor